One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050
Simiao Chen, ScD1,2; Zhong Cao, BE3,4; Klaus Prettner, PhD5,6; Michael Kuhn, PhD5,7; Juntao Yang, PhD8; Lirui Jiao, BA9; Zhuoran Wang, BSc2; Weimin Li, MD10,11; Pascal Geldsetzer, MD, ScD12; Till Bärnighausen, MD, ScD1,2,13; David E. Bloom, PhD13; Chen Wang, MD, PhD2,14,15
doi : 10.1001/jamaoncol.2022.7826
April 2023, Vol 9, No. 4, Pages 449-576
Importance Cancers are a leading cause of mortality, accounting for nearly 10 million annual deaths worldwide, or 1 in 6 deaths. Cancers also negatively affect countries’ economic growth. However, the global economic cost of cancers and its worldwide distribution have yet to be studied.
Breast Cancer Diagnosis, Treatment, and Outcomes of Patients From Sex and Gender Minority Groups
Erik Eckhert, MD, MS1; Olivia Lansinger, BA1; Victor Ritter, PhD2; Mina Liu, MS1; Summer Han, PhD2,3; Lidia Schapira, MD1; Esther M. John, PhD1,3; Scarlett Gomez, MPH, PhD4; George Sledge, MD1; Allison W. Kurian, MD, MSc1,3
doi : 10.1001/jamaoncol.2022.7146
Importance Sexual orientation and gender identity data are not collected by most hospitals or cancer registries; thus, little is known about the quality of breast cancer treatment for patients from sex and gender minority (SGM) groups.
Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer Among Survivors of Hodgkin Lymphoma
Yvonne M. Geurts, MSc1; Rebecca Shakir, MD, DPhil2; Georgios Ntentas, DPhil2,3,4; Sander Roberti, MSc1; Marianne C. Aznar, PhD5; Katinka M. John, MSc1; Johanna Ramroth, DPhil2; Cécile P. M. Janus, MD6; Augustinus D. G. Krol, MD, PhD7; Judith M. Roesink, MD, PhD8; Richard W. M. van der Maazen, MD, PhD9; Josée M. Zijlstra, MD, PhD10; Sarah C. Darby, PhD2; Berthe M. P. Aleman, MD, PhD11; Flora E. van Leeuwen, PhD1; David J. Cutter, MD, DPhil2,12; Michael Schaapveld, PhD1
doi : 10.1001/jamaoncol.2022.7153
Importance Hodgkin lymphoma (HL) survivors have higher rates of colorectal cancer, which may be associated with subdiaphragmatic radiation therapy and/or alkylating chemotherapy. Although radiation dose-response associations with breast, lung, stomach, pancreatic, and esophageal cancer after HL have been demonstrated, the association of radiation therapy with colorectal cancer remains unclear.
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast CancerA Correlative Analysis of the CALGB 40601 and PAMELA Trials
Aranzazu Fernandez-Martinez, MD, PhD1,2; Tomás Pascual, MD1,3,4,5; Baljit Singh, MD6; Paolo Nuciforo, MD, PhD7; Naim U. Rashid, PhD8; Karla V. Ballman, PhD9; Jordan D. Campbell, PhD9; Katherine A. Hoadley, PhD1,2; Patricia A. Spears, BS1; Laia Pare, PhD10; Fara Brasó-Maristany, PhD4; Nuria Chic, MD3,4,5; Ian Krop, MD, PhD11; Ann Partridge, MD12; Javier Cortés, MD, PhD13; Antonio Llombart-Cussac, MD, PhD14; Aleix Prat, MD, PhD4,5,10,15,16; Charles M. Perou, PhD1,2; Lisa A. Carey, MD1,17
doi : 10.1001/jamaoncol.2022.6288
Importance Both tumor-infiltrating lymphocytes (TILs) assessment and immune-related gene expression signatures by RNA profiling predict higher pathologic complete response (pCR) and improved event-free survival (EFS) in patients with early-stage ERBB2/HER2-positive breast cancer. However, whether these 2 measures of immune activation provide similar or additive prognostic value is not known.
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database
Daniel S. Peiffer, MD, PhD1; Fangyuan Zhao, MA2; Nan Chen, MD1; Olwen M. Hahn, MD1; Rita Nanda, MD1; Olufunmilayo I. Olopade, MD1; Dezheng Huo, MD, PhD2; Frederick M. Howard, MD1
doi : 10.1001/jamaoncol.2022.7476
Importance Given conflicting results regarding the prognosis of erb-b2 receptor tyrosine kinase 2 (ERBB2; formerly HER2 or HER2/neu)–low breast cancer, a large-scale, nationally applicable comparison of ERBB2-low vs ERBB2-negative breast cancer is needed.
Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation TherapyA Randomized Clinical Trial
Neil F. Mariados, MD1; Peter F. Orio III, DO, MS2,3; Zvi Schiffman, MD4; Thanh John Van, MD4; Alexander Engelman, MD5; Rizwan Nurani, MD6,7; Steven M. Kurtzman, MD6; Escarlata Lopez, MD, PhD8; Michael Chao, DMedSc9; Thomas P. Boike, MD10; Alvaro A. Martinez, MD10; Glen Gejerman, MD, MBA11; John Lederer, MD12; John E. Sylvester, MD13; Gregory Bell, MD14; Douglas Rivera, MD14; Neal Shore, MD15; Katie Miller, MS16; Boris Sinayuk, MD17; Michael L. Steinberg, MD18; Daniel A. Low, PhD18; Amar U. Kishan, MD18; Martin T. King, MD, PhD2,3
doi : 10.1001/jamaoncol.2022.7592
Importance Hypofractionated radiation therapy (RT) for prostate cancer has been associated with greater acute grade 2 gastrointestinal (GI) toxic effects compared with conventionally fractionated RT.
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid LeukemiaA Randomized Clinical Trial
Martin Bornhäuser, MD1,2; Christoph Schliemann, MD3; Johannes Schetelig, MD1; Christoph Röllig, MD1; Michael Kramer, MSc1; Bertram Glass, MD4; Uwe Platzbecker, MD5; Andreas Burchert, MD6; Mathias Hänel, MD7; Lutz P. Müller, MD8; Stefan Klein, MD9; Gesine Bug, MD10; Dietrich Beelen, MD11; Wolf Rösler, MD12; Kerstin Schäfer-Eckart, MD13; Christoph Schmid, MD14; Edgar Jost, MD15; Georg Lenz, MD3; Johanna Tischer, MD16; Karsten Spiekermann, MD16; Markus Pfirrmann, PhD17; Hubert Serve, MD10; Friedrich Stölzel, MD1; Nael Alakel, MD1; Jan Moritz Middeke, MD1; Christian Thiede, MD1; Gerhard Ehninger, MD1; Wolfgang E. Berdel, MD3; Matthias Stelljes, MD3
doi : 10.1001/jamaoncol.2022.7605
Importance The ideal postremission strategy in intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR) has been a matter of debate.
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung CancerPooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials
Mark A. Socinski, MD1; Robert M. Jotte, MD, PhD2,3; Federico Cappuzzo, MD4; Makoto Nishio, MD, PhD5; Tony S. K. Mok, MD6; Martin Reck, MD, PhD7; Gene G. Finley, MD8; Monika D. Kaul, MD9; Wei Yu, PhD9; Nindhana Paranthaman, MD, MBA9; Ilze B�ra, MD, MBA9; Howard J. West, MD10
doi : 10.1001/jamaoncol.2022.7711
Importance Immune-related adverse events (irAEs) arising from immune checkpoint inhibitor (ICI) cancer therapy may potentially predict improved outcomes.
Association of Social Determinants and Tumor Biology With Racial Disparity in Survival From Early-Stage, Hormone-Dependent Breast Cancer
Kent F. Hoskins, MD1,2; Gregory S. Calip, PharmD, MPH, PhD2,3,4; Hsiao-Ching Huang, MPH3; Abiola Ibraheem, MD1,2; Oana C. Danciu, MD1,2; Garth H. Rauscher, PhD2,5
doi : 10.1001/jamaoncol.2022.7705
Importance Black women with hormone receptor–positive breast cancer experience the greatest racial disparity in survival of all breast cancer subtypes. The relative contributions of social determinants of health and tumor biology to this disparity are uncertain.
Impact of Common Vitamin D–Binding Protein Isoforms on Supplemental Vitamin D3 and/or Calcium Effects on Colorectal Adenoma Recurrence RiskA Secondary Analysis of a Randomized Clinical Trial
David Corley Gibbs, MD, PhD1; Elizabeth L. Barry, PhD2; Veronika Fedirko, PhD, MPH1,3; John A. Baron, MD2,4; Roberd M. Bostick, MD, MPH1
doi : 10.1001/jamaoncol.2022.6924
Importance Variants in the vitamin D–binding protein (DBP) gene (GC) encode DBP isoforms that may affect vitamin D metabolism. However, whether these isoforms modify the effects of vitamin D3 and/or calcium supplementation on colorectal adenoma recurrence is unclear.
Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity
Benjamin Buck, MD1; Aaron P. Chum, BA1; Mitkumar Patel, MD1; Rebecca Carter, PhD1,2; Haseeb Nawaz, MD1,3; Vedat Yildiz, MS4; Patrick Ruz, BS1; Tracy Wiczer, PharmD5; Kerry A. Rogers, MD6; Farrukh T. Awan, MD, MS6,7; Seema Bhat, MD6; Avirup Guha, MD1,8; Adam S. Kittai, MD6; Orlando P. Simonetti, PhD1,9; Subha V. Raman, MD, MSEE1,10; Grant Wallace, MD1; Reynaldo Sanchez, MD1; Janice M. Bonsu, MPH1; John Gambril, MD1; Devin Haddad, MD1; James Mann, MD1,11; Lai Wei, PhD4; Onaopepo Kola-Kehinde, BS1; John C. Byrd, MD6; Jennifer A. Woyach, MD6; Daniel Addison, MD1,12
doi : 10.1001/jamaoncol.2022.6869
Importance Ibrutinib has been associated with serious cardiotoxic arrhythmias. In preclinical models, these events are paralleled or proceeded by diffuse myocardial injury (inflammation and fibrosis). Yet whether this is seen in patients or has implications for future cardiotoxic risk is unknown.
Assessment of Phase 3 Randomized Clinical Trials Including Patients With Leptomeningeal DiseaseA Systematic Review
Alisha E. Sharma, BHSc, MD(C)1; Kathryn Corbett, MD2; Hany Soliman, MD3; Arjun Sahgal, MD3; Sunit Das, MD2,4; Mary Jane Lim-Fat, MD, MSc5; Katarzyna J. Jerzak, MD, MSc2,6
Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
Ravi B. Parikh, MD, MPP1; Rebecca A. Hubbard, PhD1; Erkuan Wang, MA1; Trevor J. Royce, MD, MPH2; Aaron B. Cohen, MD, MSCE2; Amy S. Clark, MD, MSCE1; Ronac Mamtani, MD, MSCE1
Cancer in Transgender and Gender-Diverse Persons
Alberto Giovanni Leone, MD1; Dario Trapani, MD2,3; Matthew B. Schabath, PhD4; Joshua D. Safer, MD5,6; N. F. N. Scout, PhD7; Matteo Lambertini, MD8,9; Rossana Berardi, MD10; Silvia Marsoni, MD11; Francesco Perrone, MD12; Saverio Cinieri, MD13; Rosalba Miceli, PhD1; Federica Morano, MD1; Filippo Pietrantonio, MD1
doi : 10.1001/jamaoncol.2022.7173
Importance Transgender and gender-diverse individuals face unique challenges, including barriers to health care access and inequities in treatment, that may influence cancer risk and outcomes.
Worsening Rash in a Patient With Metastatic Breast Cancer
Michael J. Pierro, MD1; April J. Zhang, MD2; Lubna N. Chaudhary, MD, MS1
Improving Diversity in Clinical Trials by Using Real-world Data to Define Eligibility Criteria
Trevor J. Royce, MD, MS, MPH1,2; Yihua Zhao, PhD1; Cleo A. Ryals, PhD1
Next-Generation Alternative Payment Models in Oncology—Will Precision Preclude Participation?
Samyukta Mullangi, MD, MBA1; Ravi B. Parikh, MD, MPP2,3; Stephen M. Schleicher, MD, MBA4
Omission of Critical Information From Clinical Trial Reports—What to Do About Uninterpretable Results
Timothée Olivier, MD1,2; Alyson Haslam, PhD2; Vinay Prasad, MD2
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!
Gilberto Lopes, MD, MBA1
War and Siege Halt Gynecologic Oncology Services for Women in the Tigray Region of Ethiopia
Hale Teka, MD1; Awol Yemane, MD1; Ephrem Berhe, MD2
ERBB2-Low (Also Known as HER2-Low) Breast Cancer
Dame Idossa, MD1; Maria Borrero, MD1; Anne Blaes, MD, MS1
Increased Tumor Mutation Burden Levels and Sensitivity of Non–Small Cell Lung Cancer to PD-L1 Blockade
Xinmu Zhang, MD, PhD1; Li Zhang, MD2
Increased Tumor Mutation Burden Levels and Sensitivity of Non–Small Cell Lung Cancer to PD-L1 Blockade
Volkan Aslan, MD1; Ozan Yazici, MD1; Nuriye Özdemir, MD1
Increased Tumor Mutation Burden Levels and Sensitivity of Non–Small Cell Lung Cancer to PD-L1 Blockade—Reply
Biagio Ricciuti, MD1; Xinan Wang, PhD2; Mark M. Awad, MD, PhD1
The MaxCombo Test Severely Violates the Type I Error Rate
Dominic Magirr, PhD1; Carl-Fredrik Burman, PhD2
The MaxCombo Test Severely Violates the Type I Error Rate—Reply
Pralay Mukhopadhyay, PhD1; Satrajit Roychoudhury, PhD2; Keaven M. Anderson, PhD3
Sinoatrial Node Radiation Dose and Atrial Fibrillation in Patients With Lung Cancer
Nikhil Yegya-Raman, MD1; Salma K. Jabbour, MD2; Steven J. Feigenberg, MD1
Sinoatrial Node Radiation Dose and Atrial Fibrillation in Patients With Lung Cancer
Gerard M. Walls1; Gerard G. Hanna, PhD1
Sinoatrial Node Radiation Dose and Atrial Fibrillation in Patients With Lung Cancer—Reply
Kyung Hwan Kim, MD, PhD1; Jaewon Oh, MD, PhD2; Hong In Yoon, MD, PhD1
